Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
1,692.70
+6.80 (0.40%)
Nov 7, 2025, 3:29 PM IST
NSE:SUNPHARMA Revenue
Sun Pharmaceutical Industries had revenue of 144.78B INR in the quarter ending September 30, 2025, with 8.93% growth. This brings the company's revenue in the last twelve months to 549.64B, up 9.26% year-over-year. In the fiscal year ending March 31, 2025, Sun Pharmaceutical Industries had annual revenue of 525.78B with 8.42% growth.
Revenue (ttm)
549.64B
Revenue Growth
+9.26%
P/S Ratio
7.36
Revenue / Employee
12.78M
Employees
43,000
Market Cap
4.05T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 525.78B | 40.82B | 8.42% |
| Mar 31, 2024 | 484.97B | 46.11B | 10.51% |
| Mar 31, 2023 | 438.86B | 52.31B | 13.53% |
| Mar 31, 2022 | 386.54B | 51.56B | 15.39% |
| Mar 31, 2021 | 334.98B | 6.61B | 2.01% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 320.25B |
| Cipla | 279.66B |
| Zydus Lifesciences | 236.08B |
| Apollo Hospitals Enterprise | 225.51B |
| Biocon | 157.71B |
| Glenmark Pharmaceuticals | 134.56B |
| Alkem Laboratories | 133.04B |
| Mankind Pharma | 129.10B |
Sun Pharmaceutical Industries News
- 10 hours ago - Sun Pharma share: Nomura upgrades to buy, expects 16% upside on strong branded generics growth and favourable risk-reward - Business Upturn
- 1 day ago - Sun Pharmaceuticals Industries Ltd (BOM:524715) Q2 2026 Earnings Call Highlights: Strong Sales ... - GuruFocus
- 1 day ago - Q2 2026 Sun Pharmaceutical Industries Ltd Earnings Call Transcript - GuruFocus
- 3 days ago - Sun Pharmaceuticals Industries Ltd (NSE:SUNPHARMA) Q2 2026 Earnings Report Preview: What To Expect - GuruFocus
- 17 days ago - Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout - Benzinga
- 4 weeks ago - Stocks to Watch Today, October 9: HFCL, Coal India, Prestige Estates, GR Infra, Lupin, Senco Gold, Saatvik Green, Adani Power, Sun Pharma in focus - Business Upturn
- 5 weeks ago - Sun Pharma shares rally nearly 3% as Citi reiterates ‘Buy’ rating, says pricing overhangs now resolved after Pfizer deal - Business Upturn
- 5 weeks ago - [Brokerage Calls] Stocks to watch on October 1: Ultratech Cement, Muthoot Finance, Manappuram Finance, Amber, Syrma SGS, Sun Pharma and more - Business Upturn